One, what’s humid oxygen through a high-flow nose?
High-flowed humid oxygen (HFNC) as a new respiratory support technology has been widely applied in clinical practice in recent years. The treatment equipment consists mainly of air oxygen mixers, humid treatment units, high-flow nose plugs and connections to the respiratory tube, with a focus on providing patients with relatively constant oxygen-absorbing concentrations (21 per cent to 100 per cent), temperature (31 to 37°C) and high flow of humidity (8 to 80 L/min) gases, as well as oxygen therapy through nose plugs, which is very comfortable.
II. Structural characteristics of hydroxytherapy with a high flow of nose and humid oxygen (HFNC) can be divided into three components according to their structural characteristics.
(1) Empty oxygen mixture of gases: its effect is to mix air and oxygen at pre-set oxygen concentrations in front of turbines.
(2) The warming humid component of the gas: its effect is to warm humidification of the gas that is mixed with empty oxygen.
(3) The transport component of the gas: its effect is to ensure that the empty oxygen mixture of gas, which has completed humid warming, is transported to the patient ‘ s end at constant and constant current rates of temperature and humidity. The high-flow humid oxidizer is partially connected to the patient by high-flow nose plugs, with the sharp end of high-flow nose plugs being tilted for export, with a soft texture, fixed to the patient ‘ s face with a flexible, adjustable earband.
III. Physiological effects of hydroxytherapy with high flow of nose
(1) Provides a stable high-inhalation concentration and quick and effective improvement of blood oxygen.
(2) To flush out the physiological anatomy and reduce CO2 re-inhalation.
(3) The formation of a certain level of aerobics and their maintenance. (4) The reduction of the aerobic resistance and respiratory activity of the patient improves the respiration and partial aerobics of the patient.
(5) Adequate humidity and temperature, which optimizes the flue-coated cleaning of the gas track.
(6) Comfortable user experience, increasing dependence.
IV. Adaptation through high-flow humid oxygen treatment
1. Patients with mild and moderate hypoxiaemia (100 mmHg)/aerobic fraction (PaO2)/aerobic fraction (FiO2) < 300 mmHg), no sign of an emergency tube intubation and relatively stable vital signs;
2. Patients with mild aerobic impairments (pH7.3) may also be cautiously applied, provided that they are prepared to replace with a nPPV or a pneumatic tube to create a positive pneumatic convulsion;
3. The use of HFCs may be considered for patients who meet the criteria for the diagnosis of new coronary pneumonia in heavy weight (respiratory distress, 30 per cent breathing frequency/min; ≤93 per cent 氧 oxygen saturation in a static state; PaO2/FiO2≤300 mmHg);
4. Clinical work can be conducted in the case of acute respiratory failure type I, chronic obstructive pulmonary disease (COPD) combined with mildly moderate high-carbonate haemorrhage (pH>7.25), mechanically ventilated trachea, post-surgery, pre-oxidation of bronchial tubes, and catheters. V. Prohibition of hysteria through high flow of humid oxygen
1. A sudden stop in the heartbeat;
2. Heavy I respiratory failure;
3. Medium-heavy respiratory acid poisoning (pH<7.30);
4. Combining polyvulners is not fully functional.
VI. Parameters for humidoxin through high-flow nose flow
1. The HFC needs to have fewer parameters, mainly temperature, gas flow and oxygen concentration.
2. Temperature is generally set at 31 ~ 37 °C, which is regulated primarily on the basis of the patient ‘ s comfort and durability, while maintaining a certain viscosity of the glucose so that the acreage can easily cough out.
The gas flow is generally set at 8-80 L/min, with a maximum oxygen concentration of 100 per cent, which is based mainly on the type of respiratory failure of the patient:
4.I Respiratory failure: initial gas flow setting of 30-40 L/min; Dip-FiO2 to maintain SpO2 at 92-96 per cent, adjusted by blood-gas analysis, with a gradual increase in oxygen flow to increase the FIO2 maximum to 100 per cent if the O2 target is not met;
5. Type-II respiratory failure: The initial set-up for gas flow is 20-30 L/min, which can be set at 45-55 L/min or higher if CO2 is visible, with maximum patient tolerance; and the drop-in of FIO2 to maintain saturation (Spo2) at 88%-92%, combined with a blood-gas analysis dynamic adjustment.
Summary
In contrast to positive pressure-free gas, high-voltage oxytherapy increases the comfort and dependence of patients and thus becomes a partial substitution for non-invasive mechanical gas. Compared to the low-flow oxygen mode of regular oxygen output, high-flow oxygen treatment by nose can provide the required air current speed to match or exceed the patient ‘ s peak flow, reducing the dilution of the air, so that inhaling oxygen concentrations are not affected by such factors as the patient ‘ s breathing frequency, air flow speed, respiratory morphology, etc., and providing the patient with accurate and stable oxygen intake concentrations, which can help to improve the patient ‘ s oxygen amalgamation.
Respiratory failure
